These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35779895)

  • 1. Vitrectomy with subretinal tissue plasminogen activator (r-TPA) and intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) for submacular hemorrhages treatment: Retrospective analysis of 22 cases.
    Herranz Cabarcos A; Quiroz Quiroga MJ; Alarcón Valero I; Castilla Martí M; Pospoki V; Vilaplana Blanch D
    Arch Soc Esp Oftalmol (Engl Ed); 2022 Jul; 97(7):391-395. PubMed ID: 35779895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional and structural outcome after vitrectomy combined with subretinal rtPA Injection with or without additional intravitreal Bevacizumab injection for submacular hemorrhages.
    Rickmann A; Paez LR; Della Volpe Waizel M; Bisorca-Gassendorf L; Schulz A; Vandebroek AC; Szurman P; Januschowski K
    PLoS One; 2021; 16(4):e0250587. PubMed ID: 33930041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of pigment epithelial detachment in AMD with submacular hemorrhage treated with vitrectomy and subretinal co-application of rtPA and anti-VEGF.
    Treumer F; Wienand S; Purtskhvanidze K; Roider J; Hillenkamp J
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1115-1123. PubMed ID: 28280989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitrectomy, subretinal Tissue plasminogen activator and Intravitreal Gas for submacular haemorrhage secondary to Exudative Age-Related macular degeneration (TIGER): study protocol for a phase 3, pan-European, two-group, non-commercial, active-control, observer-masked, superiority, randomised controlled surgical trial.
    Jackson TL; Bunce C; Desai R; Hillenkamp J; Lee CN; Lois N; Peto T; Reeves BC; Steel DH; Edwards RT; van Meurs JC; Wafa H; Wang Y
    Trials; 2022 Jan; 23(1):99. PubMed ID: 35101110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of submacular hemorrhage with intravitreal versus subretinal injection of recombinant tissue plasminogen activator.
    Hillenkamp J; Surguch V; Framme C; Gabel VP; Sachs HG
    Graefes Arch Clin Exp Ophthalmol; 2010 Jan; 248(1):5-11. PubMed ID: 19669780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of submacular hemorrhage with tissue plasminogen activator and pneumatic displacement in age-related macular degeneration.
    Sniatecki JJ; Ho-Yen G; Clarke B; Barbara R; Lash S; Papathomas T; Antonakis S; Gupta B
    Eur J Ophthalmol; 2021 Mar; 31(2):643-648. PubMed ID: 31813290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fundus Autofluorescence Patterns in Subretinal Hemorrhages Associated with Neovascular Age-Related Macular Degeneration.
    Nawrocka ZA; Nawrocki J
    Ophthalmologica; 2024; 247(1):58-64. PubMed ID: 38113868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitrectomy for the treatment of submacular hemorrhages from macular degeneration: a comparison of submacular hemorrhage/membrane removal and submacular tissue plasminogen activator-assisted pneumatic displacement.
    Thompson JT; Sjaarda RN
    Trans Am Ophthalmol Soc; 2005; 103():98-107; discussion 107. PubMed ID: 17057793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of hematomas in age related macular degeneration by vitrectomy and subretinal injection of r-tPA: Preliminary results (French translation of the article)].
    Boiché M; Angioi-Duprez K; Conart JB; Berrod JP
    J Fr Ophtalmol; 2020 Jan; 43(1):43-50. PubMed ID: 31870667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgery, Tissue Plasminogen Activator, Antiangiogenic Agents, and Age-Related Macular Degeneration Study: A Randomized Controlled Trial for Submacular Hemorrhage Secondary to Age-Related Macular Degeneration.
    Gabrielle PH; Delyfer MN; Glacet-Bernard A; Conart JB; Uzzan J; Kodjikian L; Arndt C; Tadayoni R; Soudry-Faure A; Creuzot Garcher CP
    Ophthalmology; 2023 Sep; 130(9):947-957. PubMed ID: 37088447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TISSUE PLASMINOGEN ACTIVATOR FOR SUBFOVEAL HEMORRHAGE DUE TO AGE-RELATED MACULAR DEGENERATION: Comparison of 3 Treatment Modalities.
    Fassbender JM; Sherman MP; Barr CC; Schaal S
    Retina; 2016 Oct; 36(10):1860-5. PubMed ID: 26945238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of thick submacular hemorrhage with subretinal tissue plasminogen activator and pneumatic displacement for age-related macular degeneration.
    Chang W; Garg SJ; Maturi R; Hsu J; Sivalingam A; Gupta SA; Regillo CD; Ho AC
    Am J Ophthalmol; 2014 Jun; 157(6):1250-7. PubMed ID: 24531021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Submacular hemorrhage in polypoidal choroidal vasculopathy treated by vitrectomy and subretinal tissue plasminogen activator.
    Kimura S; Morizane Y; Hosokawa M; Shiode Y; Kawata T; Doi S; Matoba R; Hosogi M; Fujiwara A; Inoue Y; Shiraga F
    Am J Ophthalmol; 2015 Apr; 159(4):683-9. PubMed ID: 25555798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of recombinant tissue plasminogen activator and gas versus bevacizumab and gas for subretinal haemorrhage.
    Mayer WJ; Hakim I; Haritoglou C; Gandorfer A; Ulbig M; Kampik A; Wolf A
    Acta Ophthalmol; 2013 May; 91(3):274-8. PubMed ID: 21952010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injection for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy.
    Kitagawa Y; Shimada H; Mori R; Tanaka K; Yuzawa M
    Ophthalmology; 2016 Jun; 123(6):1278-86. PubMed ID: 26949121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of submacular massive haemorrhage in age-related macular degeneration: comparison between subretinal transplant of human amniotic membrane and subretinal injection of tissue plasminogen activator.
    Caporossi T; Bacherini D; Governatori L; Oliverio L; Di Leo L; Tartaro R; Rizzo S
    Acta Ophthalmol; 2022 Aug; 100(5):e1143-e1152. PubMed ID: 34609787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of hematomas in age related macular degeneration by vitrectomy and subretinal injection of r-tPA: Preliminary results.
    Boiché M; Angioi-Duprez K; Conart JB; Berrod JP
    J Fr Ophtalmol; 2019 Nov; 42(9):e391-e397. PubMed ID: 31471124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Literature review of recombinant tissue plasminogen activator used for recent-onset submacular hemorrhage displacement in age-related macular degeneration.
    van Zeeburg EJ; van Meurs JC
    Ophthalmologica; 2013; 229(1):1-14. PubMed ID: 23075629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pars plana vitrectomy, subretinal injection of tissue plasminogen activator, and fluid-gas exchange for displacement of thick submacular hemorrhage in age-related macular degeneration.
    Haupert CL; McCuen BW; Jaffe GJ; Steuer ER; Cox TA; Toth CA; Fekrat S; Postel EA
    Am J Ophthalmol; 2001 Feb; 131(2):208-15. PubMed ID: 11228297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitrectomy with subretinal tissue plasminogen activator and ranibizumab for submacular haemorrhages secondary to age-related macular degeneration: retrospective case series of 45 consecutive cases.
    González-López JJ; McGowan G; Chapman E; Yorston D
    Eye (Lond); 2016 Jul; 30(7):929-35. PubMed ID: 27055681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.